U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07381556) titled 'Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study' on Jan. 07.
Brief Summary: Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata. Eligibility for this treatment, in the Netherlands, requires prior failure of systemic therapies such as cyclosporin or methotrexate. However, the choice between methotrexate and cyclosporin as first-line systemic treatment is not supported by robust comparative studies.
Therefore, the investigators conduct a patient preference trial with a long-term f...